Neihulizumab (ALTB-168) in Patients With Steroid-refractory Acute Graft-versus-host Disease or Treatment-refractory Acute Graft-versus-host Disease
Completed · Phase 1
Conditions studied: Steroid-refractory Acute Graft-versus-Host Disease, Treatment-refractory Acute Graft-versus-Host Disease
In brief
A Phase I study to establish the pharmacokinetics, pharmacodynamics, safety and efficacy profiles of Neihulizumab in patients with steroid-refractory or treatment refractory acute graft-versus-host disease (SR/TR-aGVHD)
Key facts
- Study ID
- NCT03327857
- Run by
- AltruBio Inc.
- People needed
- 37
- Starts
- 2018-05-31
- Expected to finish
- 2022-12-31
- Last updated by the study team
- 2023-01-19
Who can join
Age: 12 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- City of Hope — Duarte, California, United States
- David Geffen School of Medicine at UCLA — Los Angeles, California, United States
- University of Miami - Sylvester Comprehensive Cancer Center — Miami, Florida, United States
- Emory University — Atlanta, Georgia, United States
- University of Chicago — Chicago, Illinois, United States
- The University of Kansas Cancer Center — Westwood, Kansas, United States
- Dana Farber Cancer Center — Boston, Massachusetts, United States
- University of Michigan — Ann Arbor, Michigan, United States
- University of Minnesota — Minneapolis, Minnesota, United States
- University Hospitals Seidman Cancer Center — Cleveland, Ohio, United States
- Baylor College of Medicine-Houston Methodist & Texas Children's Hospital — Houston, Texas, United States
- Fred Hutchinson Cancer Research Center — Seattle, Washington, United States
- Medical College of Wisconsin — Milwaukee, Wisconsin, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.